deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT02880956

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease

Sponsor: AbbVie

Conditions Alzheimer's Disease
Interventions ABBV-8E12 placebo for ABBV-8E12
Updated 25 times since 2017 Last updated: Aug 4, 2022 Started: Jan 26, 2017 Primary completion: Mar 30, 2021 Completion: Jul 28, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02880956, this PHASE2 trial focuses on Alzheimer's Disease and remains completed. Sponsored by AbbVie, it has been updated 25 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Oct 2019 · 6 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE2

▶ Show 20 earlier versions

  1. Sep 2021 — Apr 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Apr 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  10. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  11. Oct 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  12. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  13. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  14. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE2

  15. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  16. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  17. Jun 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  18. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  19. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  20. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, United States , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Boston, United States , Brescia, Italy , Burwood, New Zealand , Chicago, United States , Copenhagen Ø, Denmark , Dallas, United States and 50 more locations